Castanheira, H. K. Becker, P. R. Rhomberg, R. N. Jones; JMI Lab., N Liberty, IA. pneumonia KP in a Neutropenic Murine Thigh Model Lepak, K. Marchillo, W. Craig, D. R. Andes; Univ. of Wisconsin, Madi- son, WI. pneumoniae

100 SCIENTIFIC SESSIONS September 9-12 | F-842 Comparative Efficacy of BAL30072, Aztreonam, Meropenem and Ceftazidime and Effects of Dose Fractionation in a Murine Thigh Infection Model J. K. Gould 1 , A. Sattar 1 , G. M. Daws 1 , L. J. Payne 1 , J. Spikermann 2 , W. Stubbings 2 , A. Schmitt-Hoffmann 2 , M. G. P. Page 2 , P. A. Warn 1 ; 1 Euprotec Ltd. Manchester, United Kingdom, 2 Basilea Pharmaceutica Intl. Ltd. Basel, Switzerland. F-843 Broad Spectrum Cephalosporins with Urea-Substituted Pyridinium Group at the C-3’ Position Exhibiting Potent Activity against Methicillin-Resistant Staphylococcus aureus and Pseudomo- nas aeruginosa Y. He, N. Yin, J. Romero, C. Abel, R. Busch, B. Wang, A. Pearson, P. Herradura, D. Keith, J. Rock, L. Chesnel, K. Cassidy C. Monahan, S. Zhang, J. Silverman, D. Alexander, C. Metcalf Y. Gu; Cubist Pharmaceuticals, Lexington, MA. F-844 Synthesis and Structure-Activity Relationships of Aminoalkyl- N’-Pyridin-4-yl Benzohydrazide-Derived Cephalosporins with Broad Spectrum Activity against Methicillin-Resistant Staphylo- coccus aureus and Pseudomonas aeruginosa J. Romero, Y. He, N. Yin, C. Abel, R. Busch, B. Wang, A. Pearson, P. Her- radura, F. Epie, D. Keith, J. Rock, L. Chesnel, K. Cassidy, C. Monahan, S. Zhang, J. Silverman, D. Alexander, C. Metcalf-, Y. Gu; Cubist Pharmaceuti- cals, Lexington, MA. F-845 Structure-Activity Relationship Studies of Novel Cephalo- sporins with Substituted Pyrazolium Groups at the C-3’ Position against Methicillin-Resistant Staphylococcus aureus and Pseudomo- nas aeruginosa

N. Yin

1 , Y. He 1 , J. Romero 1 , C. Abel 1 , R. Busch 1 , B. Wang 1 , A. Pearson 2 , P. Herradura 3 , F. Epie 1 , D. Keith 1 , J. Rock 1 , L. Chesnel 1 , K. Cassidy 1 , C. Monahan 1 , Y. Li 1 , C. Chuong 1 , S. Zhang 1 , J. Silverman 1 , D. Alexander 1 , C. Metcalf 1 , Y. Gu 1 ; 1 Cubist Pharmaceuticals, Lexington, MA, 2 Biotech Generics LLC, Brooklyn, NY, 3 Genentech, San Francisco, CA. F-846 In Vivo Efficacy of CB-027 against Methicillin-Resistant Staphylococcus aureus, and Ceftazidime-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae Infections in Mice S. Zhang, L. I. Mortin, Y. Li, C. Chuong, H. Corkrey, C. Khang, A. Alsup, T. Li, A. Arya, Y. He, N. Yin, J. Rock, C. Abel, Y. Gu, D. Alexander, C. Metcalf, J. Silverman, C. Murphy; Cubist Pharmaceuticals, Lexington, MA. F-847 Versatile 6 ơ-hydroxymethyl Penicillanic Acid Sulfone 6 ơ-HM-sulfone Derivatives asơ-Lactamase Inhibitors

J. D. Buynak

1 , M. Nottingham 1 , C. Bethel 2 , K. Papp-Wallace 2 , D. McLeod 1 , S. R. R. Pagadala 1 , M. Winkler 3 , R. A. Bonomo 2 ; 1 SMU, Dallas, TX, 2 VAMC, Cleveland, OH, 3 CWRU, Cleveland, OH. F-848 Discovery of RPX7009, a Broad-Spectrum Beta-Lactamase Inhibitor with Utility vs. Class A Serine Carbapenemases

S. J. Hecker

1 , K. R. Reddy 1 , M. Totrov 2 , G. C. Hirst 1 , O. Lomovskaya 1 , D. C. Griffith 1 , P. King 1 , R. Tsivkovski 1 , D. Sun 1 , M. Sabet 1 , Z. Tarazi 1 , M. N. Dudley 1 ; 1 Rempex Pharmaceuticals, Inc., San Diego, CA, 2 Molsoft L.L.C., San Diego, CA. F-849 Biochemical Characterization of the Beta-Lactamase Inhibitor RPX7009 O. Lomovskaya, R. Tsivkovsky, D. Sun, D. Griffith, S. J. Hecker M. N. Dudley; Rempex Pharmaceuticals, Inc, San Diego, CA. F-850 Microbiological Characterization of Beta-Lactamase Inhibitor RPX7009 O. Lomovskaya, P. King, D. Sun, D. C. Griffith, S. J. Hecker, M. N. Dudley; Rempex Pharmaceuticals, Inc, San Diego, CA. F-851 Pharmacokinetics of the New Beta-Lactamase Inhibitor RPX7009 in Preclinical Species D. C. Griffith, M. Sabet, Z. Tarazi, O. Lomovskaya S. J. Hecker, M. N. Dudley; Rempex Pharmaceuticals, San Diego, CA. F-852 Nonclinical Toxicology and Safety Profile of the Beta-Lacta- mase Inhibitor RPX7009 D. C. Griffith, M. Sabet, Z. Tarazi, BS , R. Tsivkovski, O. Lomovskaya, S. J. Hecker M. N. Dudley; Rempex Pharmaceuticals, San Diego, CA. F-853 Activity of RPX2003 - RPX7009 Combinations against Carbapenem-Resistant Enterobacteriaceae

D. M. Livermore, S. Mushtaq, H. Dhanji; Hlth. Protection Agency, London, United Kingdom.

F-854 In Vitro Activity of RPX2003RPX7009, a Carbapenem Com- bined with a Serine ơ-Lactamase Inhibitor against Anaerobic Bacteria

E. J. C. Goldstein, D. M. Citron; R.M. Alden Res. Lab., Culver City, CA. F-855

Activity of Rpx2003rpx7009 RPX39, a Carbapenem Com- bined with a Novel ơ-Lactamase Inhibitor BLI Tested against Clinical Isolates Producing Defined Enzymes

M. Castanheira

1 , O. Lomovskaya 2 , P. R. Rhomberg 1 , R. N. Jones 1 ; 1 JMI Lab., N Liberty, IA, 2 Rempex Pharmaceuticals, San Diego, CA. F-856 Pre-Clinical Evaluation of a Carbapenem ơ-Lactamase Inhibi- tor Combination RPX2003RPX7009 Tested against Serine- Carbapenemase-Producing Pathogens

M. Castanheira, H. K. Becker, P. R. Rhomberg, R. N. Jones; JMI Lab., N Liberty, IA.

F-857 In Vivo Evaluation of a Novel Carbapenemase Inhibitor CPI, Rpx7009, in Combination with the Carbapenem Rpx2003 against 2 Kpc Producing

K. pneumonia KP in a Neutropenic Murine Thigh Model

A. Lepak, K. Marchillo, W. Craig, D. R. Andes; Univ. of Wisconsin, Madi- son, WI.

F-858 In Vivo Efficacy of the Beta-Lactamase Inhibitor RPX7009 Combined with the Carbapenem RPX2003 against KPC- Producing

K. pneumoniae

M. Sabet, Z. Tarazi , O. Lomovskaya, S. J. Hecke, M. N. DudleyO, D. C. Griffith; Rempex Pharmaceuticals, San Diego, CA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 100 G Poster Session Impact of Expanded Valent: Pneumococcal Vaccines Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: G-859 Lessons from Pneumococcal Conjugate Vaccines PCV Efficacy Trials against Community-Acquired Pneumonia CAP and Acute Otitis Media AOM

F. L. P. Fierens, B. Hoet, W. P. Hausdorff; GlaxoSmithKline Biologicals, Wavre, Belgium.